Specialty Pharmacy

Involvement with the organizations and nonprofit foundations that focus on specialty disease states can help specialty pharmacists gain perspective on the patients they treat.

Crizanlizumab (SEG101, Novartis) is being developed to prevent painful complications called vaso-occlusive crises in patients with sickle cell disease.

Study suggests a new therapy could stop tumor growth by affecting myeloid cell behavior.

Top news of the day across the health care landscape.

Community-acquired pneumonia is a major cause of mortality and morbidity among patients with HIV.

A multimethod approach including use of refill data may be the most effective method to identify nonadherence in young patients with chronic kidney disease.

Controlling the viral reaction of cells latently infected with HIV may have implications for future drug treatments.

Doris Quon, MD, Medical Director at the Orthopaedic Hemophilia Treatment Center, discusses the main takeaways from phase 3 HAVEN trial data for emicizumab (Hemlibra) prophylaxis in hemophilia.

Top news of the day across the health care landscape.

A substantial portion of mortality from liver cirrhosis and hepatocellular carcinoma can be attributed to the extrahepatic manifestations associated with hepatitis C virus.

Advancements in targeted therapies have helped significantly improve survival in late-stage anaplastic lymphoma kinase positive non-small cell lung cancer.

Top news of the day across the health care landscape.

Making the patients’ lives easier is at the heart of my job.

Top news of the week from Specialty Pharmacy Times.

A look at last week's top stories in the world of pharmacy.

Study finds that treating hepatitis C reduced the risk of developing the signs and symptoms of Parkinson disease.

New high-cost gene therapies are pushing health care providers to explore new methods to help the US health care system to fund specialty drugs.

Top news of the day across the health care landscape.

Researches seeking to eliminate HIV are close enough to see the finish line, but with no idea how far away they are from a cure.

Transcranial direct current stimulation shows promise in addressing fatigue in patients with multiple sclerosis.

The FDA has approved dasatinib (Sprycel) tablets in combination with chemotherapy for the treatment of pediatric patients with newly diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia.

Andexxa [coagulation factor Xa (recombinant), inactivated-zhzo] is the first and only antidote for patients treated with rivaroxaban or apixaban, when anticoagulation reversal is needed.

Nick Calla, RPh, vice president of Industry Relations at Cardinal Health Specialty Solutions, talks about how different providers must work together to ensure the success of a value-based care system.

Study finds at least a 1.5-fold difference between states with lowest and highest proportions of cancers related to obesity.

Top news of the day across the health care landscape.

Survivors of Hodgkin Lymphoma have higher incidence rates of breast, lung, colorectal, and thyroid cancer later in life compared with the general population, new study says.

Tim Boonstra, RPh, Pharmacy Manager at Fairview Center for Bleeding and Clotting Disorders, discusses the collaborative approach taken at his clinic in the management and treatment of patients with hemophilia.

Looking ahead, there are a plethora of promising new treatments for a range of specialty conditions in the 2019 drug pipeline.

Top news of the day across the health care landscape.

While there were many notable approvals, we’ve rounded up a list of 10 newly-approved therapies to know from 2018.